Hengrui Pharma Sets Nomination Committee to Tighten Board Governance

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ) has provided an announcement.

Jiangsu Hengrui Pharmaceuticals has established a Nomination Committee under its board to formalize the selection and review of directors and senior management, aiming to optimize board composition and strengthen corporate governance. The committee will comprise three to seven directors, with a majority of independent directors and at least one member of a different gender, and will serve concurrent terms with the board.

The Nomination Committee is tasked with setting criteria and procedures for appointing and removing directors and senior executives, assessing candidates’ qualifications, and overseeing board structure, diversity and succession planning. It will also support board performance evaluations and must publicly disclose its terms of reference, reinforcing transparency and limiting controlling shareholders’ ability to override its recommendations without sufficient justification.

The most recent analyst rating on (HK:1276) stock is a Buy with a HK$92.00 price target. To see the full list of analyst forecasts on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock, see the HK:1276 Stock Forecast page.

More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H

Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a Chinese pharmaceutical company listed in Hong Kong that operates in the healthcare and drug manufacturing industry. It focuses on developing, producing and marketing pharmaceutical products, and is subject to corporate governance standards under PRC law and the Hong Kong Stock Exchange listing rules.

Average Trading Volume: 3,328,521

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$420.7B

See more insights into 1276 stock on TipRanks’ Stock Analysis page.